Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run

Akeso has seen sharp swings in sentiment over the past few years, and investors now have fresh clinical data and a discounted cash flow lens to test whether the current share price is actually supported by the cash the business may generate. With the stock trading around HK$90.50 after a mixed run, the key issue is how those cash flows compare with the optimism reflected in the recent news flow.

• Akeso has delivered a 141.3% return over the past 3 years, which puts real weight on the question of whether that share price performance lines up with the cash the business can produce over time.

• Positive Phase III results for ivonescimab in PD L1 positive advanced non small cell lung cancer can reshape expectations for future revenue streams and the timing of cash inflows, especially if the therapy secures broader adoption in this indication.

• If you'd rather focus on sales, this one's for you. See why Akeso's 20.6x P/S tells a different valuation story .

The issue now is whether Akeso's current HK$90.50 share price is adequately explained by its cash flows when evaluated using a Discounted Cash Flow (DCF) approach.

You can also balance the Akeso story by starting a fresh watchlist of companies selected using the 179 high quality undervalued stocks as another research starting point.

Does Akeso Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on what Akeso can return to shareholders in cash over time rather than on near term earnings swings. Latest twelve month free cash flow sits at a loss of CN¥1.46b, so the whole framework leans on the expectation that the pipeline eventually flips that outflow into sustained inflows.

Analysts and internal estimates in the 2 Stage Free Cash Flow to Equity model point to recovering and then growing free cash flow in the coming decade, with projected CN¥ figures rising from the hundreds of millions into multiple billions as later years kick in. Because the Phase III HARMONi 2 data for ivonescimab gives the lead asset a clearer commercial path, the cash flow curve in this DCF still places the estimated intrinsic worth substantially above the current HK$90.50 share price. Despite that strong clinical readout lifting the story, the market price still trails what these projected cash flows suggest for long term value. Find out what Akeso could be worth using our Discounted Cash Flow (DCF) estimate .

The Akeso Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the DCF puzzle for Akeso leaves off, spelling out what sort of growth, margins and earnings trajectory would need to hold for the shares to be worth meaningfully more or less than today's price on the Community page. Each Narrative anchors a fair value to a clear storyline about Akeso's potential catalysts and key risks, which lets you track over time which version of events is gradually taking shape in the real world.